---
schema_version: "secwatch.filing_event.v1"
accession: "0001570562-22-000141"
form_type: "8-K"
ticker: "EOLS"
cik: "0001570562"
company_name: "Evolus, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:35:40.560172+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Evolus Q3 revenue +27% to $33.9M; reiterates FY2022 guidance at top end

## Summary
- Revenue $33.9M (+27% YoY); deferred $3.5M incremental due to 'Switch Your Tox' campaign, understating growth.
- FY2022 revenue guidance top end $143-150M; non-GAAP opex guidance lowered to lower half of $135-140M.
- Cash $65.6M; expects to fund through breakeven; operating cash use $17.1M, $3.8M less than Q2.
- Added 650 new accounts (total >8,800); Evolus Rewards ~450,000 members with record 100,000 redemptions.
- Launched Great Britain ops for Nuceiva; Phase II extra-strength Jeuveau enrollment completed.

## SEC filing metadata
- accession: 0001570562-22-000141
- form_type: 8-K
- ticker: EOLS
- cik: 0001570562
- company_name: Evolus, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1570562/000157056222000141/0001570562-22-000141-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1570562/000157056222000141/eols-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001570562-22-000141
- JSON: https://secwatch.observer/filing/0001570562-22-000141.json
- Plain text: https://secwatch.observer/filing/0001570562-22-000141.txt

## Key facts
- Earnings Releases
  Evolus, Inc. reported full-year 2022 results: revenue $143 to $150 million. Guidance reaffirmed.
  - Period: full-year 2022
  - Revenue: $143 to $150 million
  - Guidance: reaffirmed
  - Result: guidance update
  source text: the company continues to project full-year 2022 sales at the top end of its guidance range of $143 to $150 million, which includes a minimal contribution from international markets.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1570562/000157056222000141/0001570562-22-000141-index.htm
- Earnings Releases
  Evolus, Inc. reported third quarter ended September 30, 2022 results: revenue $33.9 million.
  - Period: third quarter ended September 30, 2022
  - Revenue: $33.9 million
  - Result: reported results
  source text: Total net revenues for the third quarter of 2022 increased 27% to $33.9 million from $26.7 million in the third quarter of 2021 driven almost entirely by higher volumes of Jeuveau
  evidence_url: https://www.sec.gov/Archives/edgar/data/1570562/000157056222000141/0001570562-22-000141-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.